SCHEMBL2966538

SCHEMBL2966538

O=C(O)c1ccc(C(=O)NCCNc2nsc3ccccc23)nc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
KCNA3 P22001 1/20 0.41
P4HTM Q9NXG6 2/20 0.40
HIF1A Q16665 2/20 0.40
P4HA1 P13674 1/20 0.40
MIF P14174 1/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
RAB9A P51151 1/20 0.40
MAPT P10636 2/20 0.40
TP53 P04637 2/20 0.40
POLB P06746 1/20 0.40
EPAS1 Q99814 1/20 0.39
PRKAA2 P54646 1/20 0.39
LMNA P02545 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2970395 0.89 TP53 (0.47) KMT2AKCNA3KDM4ENPC1ALDH1A1
SCHEMBL2969561 0.88 MAPK1 (0.46) KMT2AKCNA3KDM4EMAPTTP53
SCHEMBL2968393 0.87 KCNA3 (0.50) KMT2AKCNA3ALDH1A1MAPTTP53
SCHEMBL13220861 0.85 KMT2A (0.42) KMT2AHIF1ANPC1RAB9AMAPT
SCHEMBL2964388 0.85 HIF1A (0.45) KMT2AHIF1AMAPTEPAS1
SCHEMBL13220653 0.84 CFTR (0.39) KMT2AHIF1AMAPTTP53EPAS1
SCHEMBL13220646 0.83 HIF1A (0.37) KMT2AHIF1AMAPTTP53EPAS1
SCHEMBL2974074 0.83 HTR1A (0.51) KMT2AKCNA3ALDH1A1MAPTTP53
SCHEMBL2973242 0.83 MAPT (0.45) KCNA3KDM4EALDH1A1MAPTTP53
SCHEMBL2968291 0.82 KMT2A (0.56) KMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1853573-A1 BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION Rigel Pharmaceuticals, Inc. (US) 2007-11-14 EP claimed
US-20060229294-A1 Benzisothiazoles useful for treating or preventing HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2006-10-12 US claimed
WO-2006091858-A1 BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION RIGEL PHARMACEUTICALS, INC. (US) 2006-08-31 WO claimed
US-7776847-B2 Benzisothiazoles useful for treating or preventing HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2010-08-17 US disclosed
US-7776847-B2 Benzisothiazoles useful for treating or preventing HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2010-08-17 US disclosed
US-7776847-B2 Benzisothiazoles useful for treating or preventing HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2010-08-17 US disclosed
EP-1853573-A1 BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION Rigel Pharmaceuticals, Inc. (US) 2007-11-14 EP disclosed
US-20060229294-A1 Benzisothiazoles useful for treating or preventing HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2006-10-12 US disclosed
WO-2006091858-A1 BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION RIGEL PHARMACEUTICALS, INC. (US) 2006-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229294-A1 Benzisothiazoles useful for treating or preventing HCV infection HAVCR2, ZC3HAV1, MAVS KMT2A 2900/4885KCNA3 4492/4885P4HTM 2116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.